PMID- 31520497
OWN - NLM
STAT- MEDLINE
DCOM- 20191231
LR  - 20191231
IS  - 1601-0825 (Electronic)
IS  - 1354-523X (Linking)
VI  - 25
IP  - 8
DP  - 2019 Nov
TI  - Comparing the effectiveness and adverse effects of pilocarpine and cevimeline in 
      patients with hyposalivation.
PG  - 1937-1944
LID - 10.1111/odi.13192 [doi]
AB  - OBJECTIVES: Pilocarpine (PILO) and cevimeline (CEV) are muscarinic acetylcholine 
      receptor agonists that stimulate salivary gland function. The aim of this 
      investigation was to retrospectively run a head-to-head comparison for their 
      effectiveness and frequency of adverse effects in patients with hyposalivation. 
      METHODS: A retrospective chart review was conducted for patients seen at the Oral 
      Medicine Clinic at Tufts University School of Dental Medicine (TUSDM) and was 
      prescribed PILO or CEV. Patients' demographics, medical history/medication, 
      stimulated salivary (SS), and unstimulated salivary (US) flow recorded at the 
      initial visit and at 3- and 6-month follow-ups were collected. Changes in 
      dosage/frequency, side effects, and drug discontinuation were also reported. 
      RESULTS: A total of 110 patients' charts were reviewed. The majority of subjects 
      (91%) were females with an average age of 61. At 3-month follow-up, the use of 
      CEV showed significant improvement in SS compared to PILO (p = .033) but not in 
      US (p = .10). At 6-month follow-up, there was no significant difference in SS or 
      US between the two groups (SS: p = .09; US: p = .71). The use of PILO was 
      associated with a higher proportion of adverse effects compared to CEV (p = .04). 
      The overall adherence rate was significantly higher in the CEV group (p = .0056). 
      CONCLUSIONS: The effectiveness of CEV and PILO is comparable. However, PILO seems 
      to be associated with more reporting of side effects.
CI  - (c) 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. All rights 
      reserved.
FAU - Farag, Arwa M
AU  - Farag AM
AUID- ORCID: 0000-0003-3762-3474
AD  - Department of Oral Diagnostic Sciences, Faculty of Dentistry, King AbdulAziz 
      University, Jeddah, Saudi Arabia.
AD  - Division of Oral Medicine, Department of Diagnostic Sciences, Tufts University 
      School of Dental Medicine, Boston, MA.
FAU - Holliday, Craig
AU  - Holliday C
AD  - Tufts University School of Dental Medicine, Boston, MA.
FAU - Cimmino, Joseph
AU  - Cimmino J
AD  - Department of Research Administration, Tufts University School of Dental 
      Medicine, Boston, MA.
FAU - Roomian, Tamar
AU  - Roomian T
AD  - The Pediatric Physicians' Organization at Children's Hospital, Brookline, MA.
FAU - Papas, Athena
AU  - Papas A
AD  - Division of Oral Medicine, Department of Diagnostic Sciences, Tufts University 
      School of Dental Medicine, Boston, MA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20191008
PL  - Denmark
TA  - Oral Dis
JT  - Oral diseases
JID - 9508565
RN  - 0 (Muscarinic Agonists)
RN  - 0 (Quinuclidines)
RN  - 0 (Thiophenes)
RN  - 01MI4Q9DI3 (Pilocarpine)
RN  - K9V0CDQ56E (cevimeline)
MH  - Adult
MH  - Aged
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Middle Aged
MH  - Muscarinic Agonists/*therapeutic use
MH  - Pilocarpine/administration & dosage/*therapeutic use
MH  - Quinuclidines/administration & dosage/*therapeutic use
MH  - Retrospective Studies
MH  - Thiophenes/administration & dosage/*therapeutic use
MH  - Time Factors
MH  - Xerostomia/*drug therapy
OTO - NOTNLM
OT  - cevimeline
OT  - dry mouth
OT  - hyposalivation
OT  - pilocarpine
OT  - sialagogues
EDAT- 2019/09/15 06:00
MHDA- 2020/01/01 06:00
CRDT- 2019/09/15 06:00
PHST- 2019/06/08 00:00 [received]
PHST- 2019/08/29 00:00 [revised]
PHST- 2019/09/08 00:00 [accepted]
PHST- 2019/09/15 06:00 [pubmed]
PHST- 2020/01/01 06:00 [medline]
PHST- 2019/09/15 06:00 [entrez]
AID - 10.1111/odi.13192 [doi]
PST - ppublish
SO  - Oral Dis. 2019 Nov;25(8):1937-1944. doi: 10.1111/odi.13192. Epub 2019 Oct 8.